Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/8393
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shek, Dmitrii | - |
dc.contributor.author | Ahlenstiel, Golo | - |
dc.date.accessioned | 2024-01-23T05:02:03Z | - |
dc.date.available | 2024-01-23T05:02:03Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Chinese Clinical Oncology 12(5):47, 2023 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/8393 | - |
dc.subject | Oncology | - |
dc.subject | Hepatology | - |
dc.title | Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.21037/cco-23-44 | - |
dc.subject.keywords | Carcinoma, Hepatocellular | - |
dc.subject.keywords | Liver Neoplasms | - |
dc.subject.keywords | Antibodies, Monoclonal, Humanized | - |
dc.identifier.journaltitle | Chinese Clinical Oncology | - |
dc.identifier.department | Oncology | - |
dc.identifier.department | Gastroenterology and Hepatology | - |
dc.contributor.wslhd | Shek, Dmitrii | - |
dc.contributor.wslhd | Ahlenstiel, Golo | - |
dc.identifier.pmid | 37691347 | - |
dc.identifier.affiliation | Westmead Institute for Medical Research, Sydney, NSW, Australia | - |
dc.identifier.affiliation | Blacktown Mt Druitt Hospital, Sydney, NSW, Australia | - |
dc.identifier.facility | Blacktown | - |
dc.identifier.facility | Mount Druitt | - |
dc.identifier.facility | Westmead | - |
dc.identifier.facility | Auburn | - |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.